The role of salicylic acid in the treatment of psoriasis

International Journal of DermatologyVolume 38, Issue 1 p. 16-24 The role of salicylic acid in the treatment of psoriasis Mark Lebwohl MD, Mark Lebwohl MD From the Department of Dermatology, The Mount Sinai School of Medicine, New York, New YorkSearch for more papers by this author Mark Lebwohl MD, Mark Lebwohl MD From the Department of Dermatology, The Mount Sinai School of Medicine, New York, New YorkSearch for more papers by this author First published: 25 December 2001 https://doi.org/10.1046/j.1365-4362.1999.00500.xCitations: 97 Mark Lebwohl, md, Professor and Chairman, Department of Dermatology, The Mount Sinai School of Medicine, 5 East 98th Street, 12th Floor, New York, NY 10029 Supported in part by Scherring-Plough, Inc., Kenilworth, New Jersey Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Roenigk, HH. Skin manifestation of psoriasis. In: HH Roenigk & HI. Maibach eds. Psoriasis, 2nd edn. New York: Marcel Dekker. , 1991: 3 7. 2 Bernstein, JE, Parish, LC, Rapaport, M et al. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol.; 1986, 15, 504 507. 3 Roitt, I. Essential Immunology. 9th edn. London: Blackwell Science. , 1997: 347 370. 4 Krueger, GG. Editorial: Psoriasis therapy—observational or rational? N Engl J Med.; 1993, 328, 1845 1846. 5 Chang, EY, Hammerberg, C, Fisher, G et al. T-cell activation is potentiated by cytokines released by lesional psoriatic, but not normal, epidermis. Arch Dermatol.; 1992, 128, 1479 1485. 6 Greaves, MW & Weinstein, GD. Treatment of psoriasis. N Engl J Med.; 1995, 332, 581 583. 7 Weirich, EG. Dermatopharmacology of salicylic acid. Dermatologica.; 1975, 151, 268 273. 8 Shoss, RG & Lumpkin, LR. Current therapy of psoriasis. Am Fam Phys.; 1977, 15, 114 116. 9 Liem, WH, McCullough, JL, Weinstein, GD. Is topical therapy effective for psoriasis?: results of survey of U.S. dermatologists. J Invest Dermatol.; 1992, 98, 602(Abstract). 10 Lebwohl, M. Conventional remedies, future therapies, and alternative treatments for psoriasis. In: M Dahl & P. Lynch eds. Current Opinion in Dermatology, 1st edn. Philadelphia: Current Science.; 3–9 1993. 11 Lebwohl, M & Abel, E. Topical therapy for psoriasis. Int J Dermatol.; 1995, 34, 673 684. 12 Shroot, B. Anthralin. In: HH Roenigk & HI. Maibach eds. Psoriasis, 2nd edn. New York: Marcel Dekker. , 1991: 481 499. 13 Hjort, N, Norgaard, M., Roenigk, HH, Maibach, HI. eds. Psoriasis, 2nd edn. New York: Marcel Dekker., 1991: 473 479. 14 Kragballe, K, Gjertsen, BT, De Hoop, D et al. A double-blind comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet.; 1991, 337, 193 196. 15 Bruce, S, Epinette, WW, Funicella, T et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol.; 1994, 31, 755 759. 16 Physician's Desk Reference. 51st edn. Montvale, New Jersey: Medical Economics Co. 1997. 17 Dwyer, C & Chapman, RS. Calcipotriol and hypercalcaemia. Lancet.; 1991, 338, 764 765. 18 Guzzo, C. Recent advances in the treatment of psoriasis. Dermatol Clin.; 1997, 15, 59 68. 19 Esgleyes-Ribot, T, Chandraratna, RA, Lew-Kaya, DA et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol.; 1994, 30, 581 590. 20 Ghadially, R, Halkier-Sorensen, L, Elias, PM. Effects of petrolatum on stratum corneum structure and function. J Am Acad Dermatol.; 1992, 26, 387 396. 21 Pearlman, DL, Youngberg, B, Engelhard, C. Weekly pulse dosing schedule of fluorouracil: a new topical therapy for psoriasis. J Am Acad Dermatol.; 1986, 15, 1247 1252. 22 Van Weelden, H, Young, E, Van der Leun, JC. Therapy of psoriasis: comparison of photochemotherapy and several variants of phototherapy. Br J Dermatol.; 1980, 103, 1 9. 23 Stern, RS, Armstrong, RB, Anderson, TF et al. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. J Am Acad Dermatol.; 1986, 15, 546 552. 24 Peckham, PE, Weinstein, GD, McCullough, JL. The treatment of severe psoriasis: a national survey. Arch Dermatol.; 1987, 123, 1303 1307. 25 Pittelkow, M, Perry, HO, Muller, SA et al. Skin cancer in patients with psoriasis treated with coal tar. Arch Dermatol.; 1981, 117, 465 468. 26 Stern, RS, Laird, N, Melski, J et al. Cutaneous squamous cell carcinoma in patients treated with PUVA. N Engl J Med.; 1984, 310, 1156 1161. 27 Melski, JW, Tanenbaum, L, Parrish, JA et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol.; 1977, 68, 328 335. 28 Phillips, TJ. Current treatment options in psoriasis. Hosp Pract. ; April 1996, 15, 155 166. 29 Forman, AB & Roenigk, HH. PUVA and skin cancer. In: HH Roenigk & HI. Maibach eds. Psoriasis, 2nd edn. New York: Marcel Dekker. , 1991: 645 656. 30 Morison, WL, Momtaz, K, Parrish, JA, Fitzpatrick, TB. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol.; 1982, 6, 46 51. 31 Roenigk, HH & Maibach, HI. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol.; 1988, 19, 145 156. 32 McEvoy, GK & 33 Pilkington, T & Brogden, RN. Acitretin: a review of its pharmacology and therapeutic use. Drugs.; 1992, 43, 597 627. 34 Cunningham, WJ. Side effect profile of retinoids. In: HH Roenigk & HI. Malbach eds. Psoriasis, 2nd edn. New York: Marcel Dekker;., 1991: 769 774. 35 Ellis, CN & Voorhees, JJ. Etretinate therapy. J Am Acad Dermatol.; 1987, 16, 267 291. 36 Dicken, CH. Retinoids: a review. J Am Acad Dermatol.; 1984, 11, 541 552. 37 Pharmacopeial Convention Inc. USPDI . Drug Information for the Health Care Professional, Vol. 1. 17th edn . Tauton,Massachusetts: Rand McNally. , 1997: 1407 1409. 38 Fritsch, PO. Retinoids in psoriasis and disorders of keratinization. J Am Acad Dermatol.; 1992, 27, S8 S14. 39 Fritsch, PO, Honigsmann, H, Jaschke, E, Wolff, K. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative. J Invest Dermatol.; 1978, 70, 170 182. 40 Grupper, C & Berretti, B. Retinoid combinations. In: HH Roenigk & HI. Maibach eds. Psoriasis, 2nd edn. New York: Marcel Dekker., 1991: 775 782. 41 Mueller, W & Hermann, B. Cyclosporine A for psoriasis. N Engl J Med.; 1979, 301, 555. 42 Ellis, CN, Fradin, MS, Messana, JM et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med.; 1991, 324, 277 284. 43 Picascia, DD, Garden, JM, Freinkel, RK, Roenigk, HH. Treatment of resistant severe psoriasis with systemic cyclosporine. J Am Acad Dermatol.; 1987, 17, 408 414. 44 Palestine, AG, Nussenblatt, RB, Chan, CC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med.; 1984, 77, 652 656. 45 Penn, I & First, MR. Development and incidence of cancer following cyclosporin therapy. Transplant Proc.; 1986, 18, 210 213. 46 Birmingham, BK, Greene, DS, Rhodes, CT. Systemic absorption of topical salicylic acid. Int J Dermatol.; 1979, 18, 228 231. 47 Huber, C & Christophers, E. “Keratolytic” effects of salicylic acid. Arch Derm Res.; 1977, 257, 293 297. 48 Davies, M & Marks, R. Studies on the effect of salicylic acid on normal skin. Br J Dermatol.; 1976, 95, 187 192. 49 Baden, HP & Alper, JC. A keratolytic gel containing salicylic acid in propylene glycol. J Invest Dermatol.; 1974, 61, 330 333. 50 Roberts, DL, Marshall, R, Marks, R. Detection of the action of salicylic acid on the normal stratum corneum. Br J Dermatol.; 1980, 103, 191 196. 51 Krochmal, L, Wang, Jct, Patel, B et al. Topical corticosteroid compounding: effects on physiochemical stability and skin penetration rate. J Am Acad Dermatol.; 1989, 21, 979 984. 52 McEvoy, GK & 53 Kuokkanen, K & Zador, G. A double blind comparison of betamethasone dipropionate with salicylic acid (Diprosalic®) and budesonide ointment in the treatment of psoriasis. Curr Ther Res.; 1983, 34, 459 468. 54 Elie, R, Durocher, LP, Kavalec, EC. Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res.; 1983, 11, 108 112. 55 Kuokkanen, K. Betamethasone dipropionate and salicylic acid (Diprosalic®) in the treatment of psoriasis. Clin Trials J.; 1978, 15, 142 144. 56 Malfitan, VA. Betamethasone dipropionate and salicylic acid lotion for nonscalp dermatoses. Clin Ther.; 1983, 5, 290 298. 57 Lindemayr, H. Efficacy and tolerance of betamethasone dipropionate plus salicylic acid in the treatment of psoriasis and other steroid-responsive dermatoses. Curr Ther Res.; 1981, 29, 874 879. 58 Palatsi, M. Efficacy and tolerance of betamethasone dipropionate plus salicylic acid (Diprosalic® Lotion) in the treatment of psoriasis. Curr Ther Res.; 1981, 30, 905 911. 59 Anonymous. Physician's Desk Reference. 37th edn. Montvale, New Jersey: Medical Economics Co. 1983. 60 Taylor, JR & Halprin, KM. Percutaneous absorption of salicylic acid. Arch Dermatol.; 1975, 111, 740 743. Citing Literature Volume38, Issue1January 1999Pages 16-24 ReferencesRelatedInformation